Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Administered With a Yellow Fever Vaccine in Adults

PHASE3CompletedINTERVENTIONAL
Enrollment

900

Participants

Timeline

Start Date

February 28, 2018

Primary Completion Date

May 9, 2018

Study Completion Date

May 22, 2019

Conditions
Dengue
Interventions
BIOLOGICAL

YF-17D

YF-17D SC injection.

BIOLOGICAL

TDV

TDV SC injection.

DRUG

Placebo

Normal Saline (0.9% NaCl) SC injection.

Trial Locations (11)

13760

Regional Clinical Research Inc., Endwell

23507

Clinical Research Associates of Tidewater, Norfolk

36608

Coastal Clinical Research Inc, Mobile

44122

Rapid Medical Research Inc, Cleveland

64114

Center for Pharmaceutical Research, Kansas City

66219

Johnson County Clin-Trials, Lenexa

68134

Meridian Clinical Research LLC, Omaha

78745

Tekton Research, Austin

83462

Advanced Clinical Research, Meridian

84088

Advanced Clinical Research, West Jordan

91767

Empire Clinical Research, Pomona

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Takeda

INDUSTRY